Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-road

Trial Profile

Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-road

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms N-road
  • Most Recent Events

    • 06 Dec 2016 Results assessing deep molecular response (MR4.5) by 24 months after the initiation of nilotinib treatment, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 30 Aug 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan record.
    • 08 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top